Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 6.65M | $ 13.63M | $ 63.53M | $ 96.30M | $ 55.85M |
| Gross Profit | $ 0.00 | $ 13.63M | $ -93.65M | $ 82.54M | $ 50.00M |
| Operating Income | $ -147.70M | $ -210.28M | $ -190.51M | $ -308.39M | $ -216.99M |
| EBITDA | $ -127.02M | $ -176.58M | $ -172.23M | $ -294.63M | $ -211.14M |
| Net Income | $ -136.31M | $ -186.26M | $ -160.93M | $ -281.72M | $ -212.15M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 203.66M | $ 279.07M | $ 315.18M | $ 436.23M | $ 615.91M |
| Total Assets | $ 318.94M | $ 440.69M | $ 506.22M | $ 705.56M | $ 921.46M |
| Total Debt | $ 77.85M | $ 85.27M | $ 103.54M | $ 109.34M | $ 114.82M |
| Net Debt | $ 31.22M | $ 49.21M | $ 61.67M | $ 48.01M | $ -18.77M |
| Total Liabilities | $ 111.75M | $ 121.97M | $ 137.80M | $ 221.62M | $ 242.62M |
| Stockholders' Equity | $ 207.18M | $ 318.73M | $ 368.42M | $ 483.94M | $ 678.84M |
| Cash Flow | |||||
| Free Cash Flow | $ -112.04M | $ -123.60M | $ -138.42M | $ -283.77M | $ -213.57M |
| Operating Cash Flow | $ -106.08M | $ -122.87M | $ -132.26M | $ -248.21M | $ -162.87M |
| Investing Cash Flow | $ 111.17M | $ 12.22M | $ 112.67M | $ 166.75M | $ -324.02M |
| Financing Cash Flow | $ 5.49M | $ 99.89M | $ 85.00K | $ 9.21M | $ 453.13M |